Oliver Rolf Baumann - 27 Aug 2026 Form 4 Insider Report for Veraxa Biotech AG - Post de-SPAC (VRXA)

Reporting relationship: Director
Issuer ticker: VRXA
Reported as of: 27 Aug 2026
Net transaction value: +$75,000
SEC form: 4
Accepted by SEC: 31 Aug 2026, 16:10:24 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Oliver Baumann

Key filing fact

Oliver Rolf Baumann filed Form 4 for Veraxa Biotech AG - Post de-SPAC (VRXA) on 31 Aug 2026.

Key facts

This page summarizes Oliver Rolf Baumann's Form 4 filing for Veraxa Biotech AG - Post de-SPAC (VRXA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Aug 2026, 16:10.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: +$75,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002129436 Primary reporting owner

Baumann Oliver Rolf

Relationship: Director
Address: TALACKER 35, ZURICH, SWITZERLAND
Signature: /s/ Oliver Baumann
Signature date: 31 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRXA transaction

Ordinary Shares

Purchase

Transaction value: $75,000
Shares: +50,000
Change %: +0.87%
Price: $1.50
Shares after: 5,773,618
Date: 27 Aug 2026
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported securities are held by Akira Holding AG. The reporting person may be deemed to beneficially own such securities by virtue of their relationship with Akira Holding AG.